Quote:
Originally Posted by sailingfun
There was also a randomized clinical trial of ivermectin in patients with mild forms of COVID-19 that was published in JAMA in March 2021. That study analyzed 476 patients and found that the duration of symptoms of those who received a five-day course of ivermectin and those who were given a placebo “was not significantly different” between the two groups. “The findings do not support the use of ivermectin for treatment of mild COVID-19,” the researchers concluded.
In regards to the Jama study…
First, in the “limitations” section it admits the study group was relatively young. The median age of the study group was 37. In this age group you’re most likely to have extremely minor if any symptoms at all even if you just stay home and do nothing. If Ivermectin turns nothing into nothing you’re not going to be able to measure that. It even said that most of the study participants stayed home and just participated via phone and were able to continue to accomplish normal activities.
Second, also in the “limitations” section, it says virological assessments were not included. In other words, the study participants were not given actual tests to determine when they were officially negative. Their improvements were determined by characteristics that for most of the participants were self assessments and not accomplished by an actual doctor or nurse.
Quoted from earlier in the report…
“However, the relatively young and healthy study population rarely developed complications, rendering the study underpowered to detect such effects. Therefore, the ability of ivermectin to prevent the progression of mild COVID-19 to more severe stages would need to be assessed in larger trials.”
Third, the biggest one and in my opinion makes this study meaningless… in the “conflict of interest” section it says grants and personal fees were received from Merck. While Merck makes Ivermectin, Ivermectin is extremely cheap and Merck is in the process of helping J&J with their vaccines. Merck is also currently testing their own new version of an oral drug for Ivermectin. Although, it will still be most likely identical to Ivermectin. I’m sure Merck was completely unbiased when it came to developing this trial. Especially, since the success was done mostly by self assessments by young people who barely show any symptoms anyway.
I haven’t see one study that says it’s unclear if Ivermectin works that isn’t funded by a drug company. This would be like if there was a study to determine the best airline and United was the one that funded it.